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Abstract
Background: Although insight in schizophrenia spectrum disorders (SSD) has been associated with positive
outcomes, the effect size of previous treatments on insight has been relatively small to date. The metacognitive
basis of insight suggests that metacognitive training (MCT) may improve insight and clinical outcomes in SSD,
although this remains to be established.
Methods: This single-center, assessor-blind, parallel-group, randomised clinical trial (RCT) aims to investigate the
efficacy of MCT for improving insight (primary outcome), including clinical and cognitive insight, which will be
measured by the Schedule for Assessment of Insight (Expanded version) (SAI-E) and the Beck Cognitive Scale (BCIS),
respectively, in (at least) n = 126 outpatients with SSD at three points in time: i) at baseline (T0); ii) after treatment
(T1) and iii) at 1-year follow-up (T2). SSD patients receiving MCT and controls attending a non-intervention support
group will be compared on insight level changes and several clinical and cognitive secondary outcomes at T1 and
T2, whilst adjusting for baseline data. Ecological momentary assessment (EMA) will be piloted to assess functioning
in a subsample of participants.
Discussion: To the best of our knowledge, this will be the first RCT testing the effect of group MCT on multiple
insight dimensions (as primary outcome) in a sample of unselected patients with SSD, including several secondary
outcomes of clinical relevance, namely symptom severity, functioning, which will also be evaluated with EMA,
hospitalizations and suicidal behaviour.
Trial registration: ClinicalTrials.gov: NCT04104347. Date of registration: 26/09/2019 (Retrospectively registered).
Keywords: Schizophrenia spectrum disorders, Metacognitive training, Insight, Ecological momentary assessment
Background
Schizophrenia and related disorders remain associated
with relatively poor psychosocial outcomes [1]. Impaired
insight has been reported to be the strongest predictor
of this poor outcome in psychotic disorders [2]. How-
ever, the effect size of previous treatments on insight
changes in psychotic disorders has been relatively small
to date [3, 4], which may have been the result of not
tackling the actual underpinnings of insight in psychosis.
Several theories have been proposed to explain what
underlies ‘lack of insight’ in schizophrenia spectrum dis-
orders. First, lack of insight could be viewed as having a
function in terms of being protective or preserving self-
esteem, i.e., a denial mechanism [5]. Second, lack of
insight may also be considered as a primary symptom of
the disorder [6]. Third, the neurocognitive basis of
insight was in part supported by a meta-analysis [7],
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which also suggested that other variables, namely meta-
cognition, which was defined as ‘the ability to think of
one’s and others’ thinking’ [8, 9], may affect insight. In-
deed, patients with schizophrenia have been reported to
show metacognitive deficits [10, 11] and poorer meta-
cognitive performance is linked with impaired insight in
schizophrenia [12]. Metacognitive training (MCT) may
therefore improve insight, which should also have a
positive impact on clinical outcomes.
MCT was first developed by Steffen Moritz and Todd
Woodward [13] and is available at no cost at: http://
www.uke.de/mct. Since then, one systematic review [14]
and four meta-analyses [15–18] have replicated the posi-
tive effects of MCT on positive symptoms, particularly
delusions, when compared with ‘treatment as usual’
(TAU), although one meta-analysis [19] failed to show
such an association. However, to the best of our know-
ledge no definitive randomised clinical trial (RCT) using
MCT has considered insight as primary outcome to date,
although three previous RCTs found other non-MCT
metacognitively oriented therapies to improve insight in
first-episode psychosis [20] and schizophrenia [21, 22].
Clinical and cognitive insight are different, albeit re-
lated, concepts [2, 12]. There has been a growing inter-
est in clinical insight in psychosis since the
multidimensional model of insight proposed by David
[23], which encompasses three different, albeit overlap-
ping, dimensions - illness recognition, symptom relabel-
ling and treatment compliance – and has been
consistently replicated ever since [24]. Multidimensional
measurement scales, such as the Scale of Unawareness
of Mental Disorder (SUMD) [25] and the Schedule for
Assessment of Insight (SAI-E) [26], were also devised for
research. Cognitive insight is a core metacognitive do-
main which refers to the person’s ability to evaluate and
correct his/her own distorted beliefs and misinterpreta-
tions (self-reflectiveness) and the tendency to overconfi-
dence in one’s conclusions (self-certainty) [10].
The main aim of this RCT is to test whether MCT
can improve insight, including clinical and cognitive
insight, in patients with schizophrenia over a 1-year
follow-up. As secondary aims, we will investigate the ef-
fect of MCT-related insight changes on clinical out-
comes, including symptomatic severity, hospitalizations,
suicidal behaviour and psychosocial functioning. In
addition, we will pilot the use of ecological momentary
assessment (EMA) via two web-based applications -
www.MEmind.net [27] and the Evidence-Based Behav-
iour platform eB2 app [28] - to measure functioning in a
subsample of participants.
Specifically, the following five hypotheses are to be
tested: i) that MCT will result in higher cognitive and
clinical insight levels and that MCT-induced insight im-
provement will be linked with ii) reduced symptom
severity and iii) hospitalizations, iv) lower suicide rates
and v) better functioning than in controls.
Methods
Study design
This is a single-center, assessor-blind, parallel group,
two-armed randomised controlled trial (RCT) over a 1-
year follow-up period. Participants will be assessed at
baseline (T0), following which they will be randomised
to either group MCT (experimental group) or a support
group (control group) and they will be reassessed after
treatment, i.e., at approximately 8 weeks (T1), and at 1-
year follow-up (T2).
The study protocol has been approved by the local Re-
search Ethics Committee of the Instituto de Investiga-
ción Sanitaria (IIS)-Fundación Jiménez Díaz (Madrid,
Spain), from which patients will be recruited as detailed
below, and registered as RCT-EC044-19_FJD_HRJC.
Also, the protocol is registered at ClinicalTrials.gov
(NCT04104347).
Sample and eligibility criteria
The sample comes from the Centro de Salud Mental de
Arganzuela, which is an outpatient clinic linked with
Hospital Universitario Fundación Jiménez Díaz (FJD),
which provides publicly-funded medical and mental
healthcare to approximately 500,000 inhabitants residing
in our geographic catchment area in Madrid (Spain).
Those adults (age 18–64 years) with a confirmed diagno-
sis of psychosis according to the Mini International
Neuropsychiatric Interview, 5th Edition (MINI) [29], will
be invited to participate in the study. The exclusion cri-
teria will be as follows:
 IQ ≤ 70 as measured by the short form of the
Wechsler Adults Intelligence Scale (WAIS)-IV [30].
 History of head injury and/or a neurological
condition.
 Having received a metacognitively oriented therapy
within the previous year.
 Low level of Spanish.
 Lack of cooperativeness with the assessment and/or
“intervention”.
Therefore, the initial recruitment is unselected, that is,
all adults (age 18–64 years, both inclusive) with a con-
firmed diagnosis of schizophrenia spectrum disorder re-
ceiving mental healthcare in our outpatient clinic
(hence, clinically stable – i.e., not acutely unwell -) could
be included in the study, provided they do not meet any
of the above exclusion criteria. This approach has, of
course, advantages and disadvantages, which are dis-
cussed further in the section of discussion. Those who
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agree to take part in the study will be asked to give writ-
ten informed consent.
Recruitment process
Recruitment will occur at the outpatient clinic known as
Centro de Salud Mental de Arganzuela at which two
consultant psychiatrists (LMI, SSA) and one consultant
psychologist (LML) will refer potential candidates to the
principal investigator of the project (JDLM) to arrange a
first pre-recruitment interview during which the relevant
information of the project is explained to the candidate
in lay terms, including an information leaflet. Those
agreeing to participate in the study are screened against
the above inclusion/exclusion criteria at this point.
Those who are found to fulfill the study selection criteria
undertake a neurocognitive assessment. Specifically, the
WAIS-IV [30] is administered by a MSc-level clinical
psychologist (VGRR) in order to rule out an IQ ≤ 70,
which is an exclusion criterion. Those with an IQ > 70
are administered the Trail Making Test (TMT) [31],
which assesses executive function and has been found to
correlate with insight scores in psychosis patients [32],
by VGRR shortly after the WAIS-IV in order to
complete the baseline neurocognitive assessment at this
point.
After a short break of around 5min, JDLM performs
the MINI [29] to confirm the diagnosis of psychosis and
conducts the psychopathological, insight, metacognitive
and functioning assessments detailed below. Also, a set
of demographic and clinical variables, which are listed
below, are collected at this baseline interview.
All participants will be encouraged to continue taking
medication as prescribed by the treating consultant
psychiatrist, usually antipsychotics, and to receive non-
metacognitive oriented psychotherapy, such as psychoe-
ducation. There will be no restrictions on medication
changes over the trial, which can be made by the treat-
ing consultant at any time, although medication-related
variables will be considered in secondary analyses as po-
tential mediators/confounders. Participants are informed
of their right to drop out of the study at any time with-
out having to disclose a specific reason, which will have
no implications on treatment or service provision. Par-
ticipants are not compensated with any amount of
money for completing the assessments and/or receiving
the interventions, namely MCT or attending a weekly
support group.
Randomisation and assessor-blindness
After the baseline (T0) assessment participants are ran-
domised to either MCT or the support group, both of
which are run by VGRR and ASEM, through a comput-
erized plan (no stratification factors) in blocks of 10 sub-
jects (maximum number of each group) and assessor
(JDLM)-patient blind. Only one co-principal investigator
of the project (EBG) has access to the randomisation
plan, but the assessor (JDLM) is not informed of the pa-
tient’s allocation group, thus ensuring assessor-blindness
since the patient may find out what intervention he/she
is receiving, for which the study cannot be considered to
be double-blind, although it is ‘single-blind’, that is, ‘as-
sessor-blind’. Also, big efforts will be made on the
ground to reduce the risk that the assessor (JDLM) may
become accidentally unblinded and patients are
reminded that they should not disclose their group as-
signment at any time. At the end of the baseline assess-
ment, participants receive an envelope with the
intervention assignment from an independent adminis-
trator who is not involved in the research team. A re-
minder mobile text-message is also sent to participants
within the next 24 h with the group details (date, time
and venue), which is also re-sent again during the 24 h
prior to the appointment, which is very similar to our
routine clinical practice. Hence, assessor-blindness is
guaranteed at all times throughout the study period
since the assessor (JDLM) is not involved in the
randomization plan or the active interventions. See the
CONSORT flowchart in Fig. 1, below, for details.
Assessments
Participants will be assessed at three timepoints: i) T0: at
baseline; ii) T1: after treatment; iii) T2: at 1-year follow-
up. Data on different variables will be collected at each
of these assessments, which is detailed in the SPIRIT
flowchart shown in Table 1, below.
Both raters (JDLM and VGRR) completed a rater-
training workshop and received individual training in
which they were observed as they assessed pilot patients
by using the project scales explained below under the
supervision of a senior consultant psychiatrist with ex-
pertise in the use of these instruments (EBG).
Outcome measures
Co-primary outcomes
Insight is the primary outcome of this RCT and both
clinical and cognitive insight will be considered.
 Clinical insight will be measured with the Spanish
version [33] of the Schedule for Assessment of
Insight, expanded version (SAI-E) [26]. The SAI-E
takes the form of a semi-structured interview which
enquires about different aspects of insight and pro-
vides scores on three insight dimensions in line with
David’s model [23] - illness recognition, symptom
relabeling, treatment compliance - and a total
insight score. The scale was found to be easily ap-
plicable in routine clinical practice [34] and good to
excellent inter-rater reliability was reached, with
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total insight scores intra-class correlations coeffi-
cients ranging from 0.92 to 0.98 (p < 0.001) [35].
JDLM received training from the scale author (ASD)
and they both co-led the validation study of the
SAI-E Spanish version [33], which will be used in
this RCT.
 Cognitive insight will be assessed by the Spanish
version [36] of the Beck Cognitive Insight Scale
(BCIS) [10], which is a 15-item self-administered
scale which evaluates self-reflectiveness (9 items)
and self-certainty (6 items). A composite index can
thus be calculated by subtracting self-certainty from
self-reflectiveness. Internal consistency was found to
be acceptable (Cronbach’s α = 0.60–0.68) [37].
Secondary outcomes
Secondary outcomes of this investigation include symp-
tomatic severity, hospitalizations, suicidal behaviour,
metacognition, neurocognition and functioning.
Symptomatic severity Symptoms severity will be rated
with the Spanish version [38] of the Positive and Nega-
tive Syndrome Scale (PANSS) [39]. Based on a system-
atic review of previous PANSS factor analyses [40], five
symptomatic dimensions will be analysed: positive, nega-
tive, disorganization, mania and depression, which will
also be measured with the Calgary Depression Scale for
Schizophrenia (CDSS) [41].
Hospitalizations Number of hospitalizations, i.e., time
to hospitalization (i.e., survival analyses, see statistical
analyses below), and total number of days in hospital
will be considered. Mental health presentations to the
emergency department will be included in secondary
analyses.
Suicidal behaviour In order to investigate the effects of
MCT on suicidal behaviour, time to first suicidal event,
including suicide attempts and suicide completions,
Fig. 1 Study CONSORT chart. Estimated flow of participants over the trial period
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over the 1-year follow-up study period will be
investigated.
Functioning Functioning will be recorded through the
Global Assessment of Functioning (GAF) [42], the
World Health Organization Disability Schedule (WHO-
DAS) [43] and the Satisfaction Life Domains Scale
(SLDS) [44]. In addition, as a relatively novel method-
ology in patients with psychotic disorders, ecological
momentary assessment (EMA) [27] will be piloted in a
subsample of those participants who agree to set up two
web-based applications in their smartphones, namely
Memind (www.memind.net) and eB2 [28]. Memind is an
‘active’ platform which has two different interfaces or
views, namely staff and patient view. The ‘electronic
health record’ allows staff to electronically record data
on sociodemographic, diagnostic and pharmacological
variables, while the patient view was designed in order
for patient to self-rate some scales such as the BCIS
[10], which will be one of the primary outcome mea-
sures in this RCT as detailed above. On the other hand,
Evidence-Based Behavior (eB2) is a ‘passive’ platform de-
signed for recording functioning-related data, such as
mobility, i.e., location, distance, speed; physical activity
Table 1 SPIRIT flowchart
MCT Metacognitive Training. PSE Psychoeducation. MINI Mini International Neuropsychiatric Interview, 5th Edition [29]. WAIS Wechsler Adult Intelligence Scale [30].
TMT Trail Making Test [31]. BCIS Beck Cognitive Insight Scale (BCIS) [10]. SAI-E Schedule for Assessment of Insight, expanded version [26]. PANSS Positive and
Negative Syndrome Scale [38, 39]. CDSS Calgary Depression Scale for Schizophrenia [41]. GAF General Assessment of Functioning [42]. WHODAS World Health
Organization Disability Schedule [43]. SLDS Satisfaction Life Domains Scale [44]. PAS Premorbid Adjustment Scale [47]. ERTF Emotional Recognition Test Faces [51]
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i.e., number of steps, sleep data; social activity, i.e.,
phone use, active apps, social network data and emo-
tions, i.e., prosodic analysis of speech signals and text
message emotion analysis), without the subject’s collab-
oration (it is ‘passive’). Data are anonymised and sent to
a secure server. Memind and eb2 will be combined to
create a machine learning mental health system allowing
a continuous feedback from digital phenotyping [45].
Additional variables
Demographic and clinical data At baseline data on the
following demographic and clinical variables will be col-
lected: gender, age at the study inception, nationality, eth-
nicity, marital status, education level, living status,
employment status, ICD-10 diagnosis, duration of un-
treated psychosis (which will be estimated with the Not-
tingham Onset Schedule, [46], number of previous
admissions, number, date and method of previous suicidal
acts, current medications, alcohol/illicit drugs dependence
(present/absent, medical comorbidities (present/absent)
family history of mental illness (present/absent).
Marital status, living status and employment status will be
reassessed at 1-year follow-up as measures of functioning.
Premorbid adjustment Premorbid adjustment, which
can be defined as ‘the degree of achievement of develop-
mental goals’ will be retrospectively rated with the Pre-
morbid Adjustment Scale (PAS) [47]. Specifically, the
PAS provides scores on the level of adjustment over i)
childhood (to age 11), ii) early adolescence (age 11–15),
iii) late adolescence (age 15–17) and iv) adulthood (age ≥
18). With regard to childhood and adolescence, items
inquiry about sociability and social withdrawal, peer re-
lationships, scholastic performance, adaptation to school
and ability to form socio-sexual relationships. The ques-
tions regarding adulthood focus on social relationships
by asking about educational achievement, social relation-
ships and level of interest in, and enjoyment of, major
life activities, such as work or family.
Neurocognition The neurocognitive assessment battery,
which will be administered at the three assessments, will
include the short version of the Wechsler Adult
Intelligence Scale (WAIS) Revised [30], which estimates
current intelligence quotient (IQ), and the Trail Making
Test (TMT) [31], which assesses executive function.
Subtracting time in seconds to complete TMT task B
minus time in seconds to complete TMT task A gives a
measure of executive function, whilst controlling for
processing speed.
Metacognition Three metacognitive tasks will be com-
pleted by participants at the three assessments (T0, T1, T2):
 Jumping to Conclusions (JTC) will be determined
with the beads task [48].
During this task, the individual is asked to decide
the jar to which the extracted bead belongs on the
basis of probability (in task 1 the probability is 85:15,
while in task 2 the probability is 60:40). ‘JTC’ is
considered as making a decision after extracting one
or two beads.
 The Hinting Task [49, 50] will be used to measure
Theory of Mind (ToM) performance. Learning is
avoided by using different stories at the three
assessments. Cronbach’s α was good (0.64) for the
Spanish version [37].
 In addition, the Emotional Recognition Test Faces
[51], which is composed of 20 different pictures
representing people’s emotions, will be used to
evaluate ToM.
Intervention
Participants will be randomised either to receive (in
addition to their usual treatment, including antipsychotic
medication) MCT or to attend a support group. Both
‘interventions’ are implemented for the same duration
(one session per week lasting for about 45–60min over
8 weeks). Unlike comparing MCT with ‘treatment as
usual’ (TAU), controls will attend a weekly support
group to avoid group attendance-related biases, consist-
ent with some previous RCTs on MCT [37].
Metacognitive training (MCT)
Metacognitive Training (MCT) was first developed in
Germany in 2007 by Steffen Moritz and Todd Wood-
ward [13] targeting positive psychotic symptoms of
patients with schizophrenia. In short, MCT seeks ‘to
plant the seeds of doubt’ regarding cognitive biases
leading to delusional thoughts rather than asking pa-
tients to talk about of their problems, which is likely
to be distressful, particularly within the context of a
group. MCT consists of ten group sessions focused
on different topics (Modules) as follows: Attributional
Style (Module 1), Jumping to Conclusions (Modules 2
and 7), Changing Beliefs (Module 3), Empathy (Mod-
ules 4 and 6), Memory (Modules 5), Depression and
Self-Esteem (Module 8) and two additional modules,
namely Self-Esteem (Module 9) and Stigma (Module
10). Modules 8 (Self-Esteem), 9 (Self-Esteem) and 10
(Stigma) can be delivered together as one session so
the intervention totals eight weekly sessions, that is,
8 weeks. The therapists who will deliver MCT to par-
ticipants of this RCT (VGRR and ASEM) undertook
training from one of the co-authors of the Spanish
version of the MCT manual (MLBE), which is
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available at: http://www.uke.de/mkt and was directly
supervised by Steffen Moritz.
Support group
Controls will attend eight weekly support groups. In line
with the ‘treatment as usual’ delivered to most patients
with psychosis in our clinic, seven sessions will focus on
the following topics: 1) basic activities of daily living
(BADL), 2) instrumental activities of daily living (IADL),
3) physical health, 4) press-based work, 5) psychoeduca-
tion on emotions, 6) psychoeducation on illness, 7) so-
cial and family relationships. One additional session will
give participants some time to openly raise general is-
sues and concerns which were not discussed during the
above sessions. In order to minimise the effect of this
‘intervention-like’ on controls, the interaction/input
from the therapists (VGRR and ASEM) will be minimal.
Thus, controls will be encouraged to attend these group
sessions, from which they can benefit. While not an
intervention as such, this should turn into enough incen-
tive to reach similar attendance rates in both arms of the
RCT.
Treatment fidelity will be looked at by recording a ran-
dom selection of MCT sessions (after obtaining consent
from participants), which will be independently assessed
against the manual criteria (http://www.uke.de/mkt) by
two researchers from our group (MLBE and EBG) with
no involvement in the assessments or interventions.
These two researchers will also determine whether con-
trols may have been significantly exposed to elements of
metacognition by accident during the group sessions.
In addition to the randomisation group intervention, all
participants will have full access to their treatment so they
are expected to continue taking medication and receiving
non-metacognitive-based psychotherapies as recommended
by the treating multidisciplinary team. This will also allow
early identification of potential adverse events, unintended
effects of the trial and trial misconduct.
Statistical analysis
Participants’ data will be analysed at the end of the study
on an intention-to-treat (ITT) basis, thus including all pa-
tients with baseline information available. Imputation
methods will be used to estimate missing values. All the
analyses will be performed with the Statistical Package for
Social Science version 25.0 (SPSS Inc., Chicago, IL, USA).
First, demographic and clinical characteristics of
groups (MCT and controls), including insight measures,
will be compared at baseline so parametric and non-
parametric tests will be used as appropriate. Also, for de-
scriptive purposes, between-arm completion rates differ-
ences will be analysed at the end of the study.
Second, in order to investigate the primary outcome of
the study, namely insight changes over the trial period,
univariate analysis of covariance (ANCOVA) models will
examine between-group differences (MCT and controls)
in the SAI-E and BCIS total and subtotal scores changes
from T0 to T1 and from T0 to T2 (as the dependent
variable), whilst adjusting for baseline data. Hence, the
effects of treatment (independent of time) and treatment
group allocation*time interactions on insight changes
will be investigated. We will also explore within-group
scores changes between T0, T1 and T2. Specifically, we
will estimate effect sizes (Cohen’s d) and the corre-
sponding 95% confidence intervals (CI) from the im-
puted datasets for between- and within-group insight
scores changes. In accordance with Cohen’s conventions
[52], effect sizes will be classified as ‘small’ (d < 0.2),
‘medium’ (d = 0.2–0.5) or ‘large’ (d > 0.8). Due to mul-
tiple testing and the subsequent risk of type I error, re-
sults will be adjusted using Bonferroni correction.
Third, for the secondary outcomes evaluated with con-
tinuous variables, i.e., symptom severity (PANSS and
CDSS) and functioning (GAF, SDLS and WHODAS),
analogous ANCOVA models will be used. For those bin-
ary secondary outcomes, namely suicidal behaviour and
readmissions, survival analyses, i.e., multivariable Cox re-
gression models [53], will model time to the outcome
event (i.e., first suicidal event or hospital admission, re-
spectively) or the censoring date as appropriate, whilst
adjusting for baseline variables.
Finally, variables inter-relationships over the trial
period will be examined by means of path analysis
through structural equation modeling, thus testing the
effect of putative mediators/moderators/confounders/co-
variates, including neurocognition measures, on the
above associations.
Power calculations and estimation of sample size
Given that the mean SAI-E score for psychosis patients
is 13/28 with a standard deviation of around 6 [32, 35], a
difference of 2 points (e.g., 13 vs. 15) between groups
(e.g., MCT vs. controls), which is considered to be clinic-
ally meaningful [26], is equivalent to an effect size of 0.33
with a two-tailed alpha significant level set at 5%. Under
these assumptions, for reaching a sufficient statistical
power of β = 80% at the end of the study, we will need n =
63 subjects in each arm, that is, a total sample size of N =
126 patients, who will be analysed at the end of the study
on an intention-to-treat (ITT) basis. Attrition rates in pre-
vious RCTs investigating MCT effects on symptoms were
low (approximately 10%) [18]. However, since we will
follow-up patients over a more prolonged period (1 year)
we have conservatively assumed a much higher drop-out
rate of 50%. Under this assumption, the study will be car-
ried out with an initial sample size of N = 252 patients, i.e.,
n = 126 participants in each group/arm at the study
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inception, which will also allow both ITT and ‘per proto-
col’ analyses with sufficient power. See the CONSORT
flow chart in Fig. 1 for details.
Discussion
Relevance and impact
This is the first large RCT testing the long-term ef-
fects of group MCT on clinical and cognitive insight
in addition to several relevant clinical outcomes in a
representative sample of patients with schizophrenia
spectrum disorders. Although MCT has been consist-
ently demonstrated to improve positive symptoms
[14–18], the benefits of MCT on insight are yet to be
established [3], which is of major clinical relevance
given the association of insight with outcomes in
schizophrenia and related disorders [2]. This is sup-
ported further by three previous trials which revealed
other non-MCT metacognitively oriented treatments
to have a positive impact on insight [20–22].
The clinical relevance will be immediate in raising cli-
nicians’ awareness of insight, particularly regarding its
role in clinical outcomes. In addition, this RCT will add
to the field by showing the possibility of improving
insight through an eassily applicable intervention such
as MCT, which represents a more patient-centred treat-
ment approach.
Outcome measures
In addition to the primary outcome of this RCT, namely
insight, we will consider several clinical outcomes, both
positive and negative, such as symptom severity, func-
tioning, readmissions and suicidal behaviour, thus test-
ing the so-called ‘Insight Paradox’ [54]. Although the
positive impact of MCT on symptoms has been estab-
lished [14–18], most of previous RCTs included in these
meta-analyses compared MCT with TAU. Therefore,
not only this RCT may replicate this, but also by compar-
ing the MCT group with an active intervention control
group, if the above positive effect was shown, this would
provide further support for the benefits of MCT on symp-
toms. Beyond and above the effects of MCT on symptoms,
functioning will be comprehensively examined, consist-
ently with current guidelines focused on recovery as main
outcome measure [55]. Also, functioning will be evaluated
with novel methodology such as EMA, which has not been
sufficiently researched in psychosis patients.
However, insight was also linked with negative out-
comes. In particular, insight was thought to lead to de-
pression, hopelessness and suicidality, which is known as
the demoralization syndrome [56, 57] or ‘Insight Para-
dox’ [54]. However, recent research did not show a ‘dir-
ect’ relationship between insight and suicidality in first-
episode psychosis, which was due to the confounding ef-
fects of previous suicide attempts and depression on
such an association [32]. The question therefore arises,
i.e., whether an insight improving intervention (such as
MCT, which is to be tested in this trial) may reduce sui-
cide risk (and improve mood) in psychosis, which will be
properly investigated in this RCT. In addition to suicidal
behaviour-related outcomes, we will test whether MCT
can reduce admissions over the trial period, which is of
relevance from a cost-effectiveness perspective [58].
Methodological issues
Insight, which is the primary outcome of the study, will
be measured with the multidimensional SAI-E scale [26]
based on the multidimensional David’ model of insight
[23]. This will allow us to look at the effects of MCT on
insight dimensions individually, which may differ.
Recruitment and retention of patients in psychosis re-
search is challenging, particularly in long-term studies.
Accordingly, given our 1-year follow-up study period we
have decided to invite all those potentially eligible pa-
tients who are seen at our clinic during the 6-month en-
rolment period. This approach has, of course, strengths
and weaknesses. On the one hand, the sample will be
very likely to be representative of the local population of
psychosis patients, most of whom are, to some degree,
chronic (rather than early-onset psychosis patients). On
the other hand, the inclusion of chronic patients may re-
duce the room for improvement. However, it is precisely
this group of patients, which tends to be relatively
neglected by research and stakeholders in comparison
with first-episode patients, who may particularly benefit
from receiving MCT. Moreover, this design will allow us
to examine whether chronicity, including (mild) cogni-
tive impairment, mediates the response to MCT, i.e., by
comparing response to MCT (in comparison with con-
trols) in chronic and early-onset patients. Nevertheless,
those with an IQ ≤ 70 will be excluded from the study.
Unlike most of previous studies, both controls and the
intervention group (MCT) will attend similar weekly group
sessions at the clinic with support from the clinical team,
thus minimising stigma-related issues. When designing the
study with an active control group, we were aware that we
were reducing the room for improvement, that is, the likeli-
hood of finding between-group differences in terms of
insight and the other secondary outcomes of interest,
namely symptom severity, admissions, suicidal behaviour
and functioning. However, this design will represent a more
challenging test for MCT to demonstrate whether it should
be incorporated into routine clinical practice and guide-
lines. Thus, this approach will make the trial more similar
to our routine practice since patients regularly attend
psychoeducation-like/supportive groups at our clinic at staff
(psychiatrists and psychologists) discretion on the basis of
regular individualised needs assessments, which may also
maximise completion rates among controls. Nevertheless,
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participants will be reminded via mobile text message their
next group appointment within the previous 24 h. In
addition, it is worth noting that from an ethical perspective,
although controls will be prevented from receiving MCT,
at least they will be able to attend a weekly supportive
group at the outpatient clinic, from which they may benefit
in addition to their treatment as usual.
With regard to the statistical analyses, two points de-
serve some comment. First, the effect of variables
changes over time on outcome measures will be consid-
ered since survival analyses will be performed. Second,
by using path analysis we will be able to better under-
stand the causality relationships between the variables
tested in the models, which is what really matters. In
addition, devising new dynamic probabilistic models to
extract knowledge in the form of digital biomarkers ob-
tained jointly from the patient’s EMA and electronic
health records should contribute to paving the way to-
wards the so-called personalized medicine.
Strengths and weaknesses
At this pre-recruitment stage, we already acknowledge
that this RCT has strengths and weaknesses. In particular,
we intend to recruit a large sample size of SSD patients
who will also be representative of our local population
since most of our psychosis patients receive mental
healthcare in our clinic with the exception of a tiny pro-
portion in either primary care or in the private sector. As
detailed above, controls will also attend a weekly ‘thera-
peutic-like’ group, thus controlling for the effect of attend-
ing a group, which will represent a more challenging test
for MCT. In addition, the main authors of MCT, Steffen
Moritz and Todd Woodward, will not get directly in-
volved in this RCT, thus avoiding allegiance-related biases.
Of course, the vast majority, if not all, patients are ex-
pected to continue taking medication as prescribed, par-
ticularly antipsychotics, so medication-related variables
will be included in secondary analyses since they may
affect the effect of MCT on insight.
However, this is a RCT so participants are required to
give consent and complete a comprehensive set of assess-
ments. Hence, those with the lower levels of cooperative-
ness, and therefore with poorer insight, are not likely to
take part in this study, which may limit the generalisability
of the results. Nevertheless, this ethical requirement, and
the subsequent limitation in terms of generalisability, ap-
plies to most studies on insight in psychosis.
Conclusions
To sum up, to the best of our knowledge this will be the
first RCT investigating the effect of group MCT on mul-
tiple dimensions of cognitive and clinical insight (as co-
primary outcomes) in a real-world sample of unselected
patients with SSD. Also, the impact of these potential
MCT-related insight changes on several secondary clin-
ical outcomes, such as symptom severity, functioning,
which will be also assessed with EMA, hospitalizations
and suicidal behaviour, will be looked at.
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